摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-((1-(2-chlorophenyl)-1H-pyrazol-5-yl)oxy)aniline | 1039053-28-5

中文名称
——
中文别名
——
英文名称
2-((1-(2-chlorophenyl)-1H-pyrazol-5-yl)oxy)aniline
英文别名
——
2-((1-(2-chlorophenyl)-1H-pyrazol-5-yl)oxy)aniline 化学式
CAS
1039053-28-5
化学式
C15H12ClN3O
mdl
——
分子量
285.733
InChiKey
HKXCMUVXGCMVRO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    20.0
  • 可旋转键数:
    3.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    53.07
  • 氢给体数:
    1.0
  • 氢受体数:
    4.0

反应信息

  • 作为反应物:
    描述:
    2-((1-(2-chlorophenyl)-1H-pyrazol-5-yl)oxy)aniline 4-三氟甲氧基苯基异氰酸酯三乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 16.0h, 以16%的产率得到1-{2-[2-(2-chloro-phenyl)-2H-pyrazol-3-yloxy]-phenyl}-3-(4-trifluoromethoxy-phenyl)-urea
    参考文献:
    名称:
    P2Y1 receptor antagonists as novel antithrombotic agents
    摘要:
    The P2Y(1) and P2Y(12) purinergic receptors are responsible for mediating adenosine diphosphate (ADP) dependent platelet aggregation. Evidence from P2Y(1) knockout studies as well as from nucleotide-based small molecule P2Y(1) antagonists has suggested that the antagonism of this receptor may offer a novel and effective method for the treatment of thrombotic disorders. Herein, we report the identification and optimization of a series of non-nucleotide P2Y(1) antagonists that are potent and orally bioavailable. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.04.028
  • 作为产物:
    描述:
    铁粉氯化铵 作用下, 以 乙醇 为溶剂, 反应 3.0h, 以62%的产率得到2-((1-(2-chlorophenyl)-1H-pyrazol-5-yl)oxy)aniline
    参考文献:
    名称:
    P2Y1 receptor antagonists as novel antithrombotic agents
    摘要:
    The P2Y(1) and P2Y(12) purinergic receptors are responsible for mediating adenosine diphosphate (ADP) dependent platelet aggregation. Evidence from P2Y(1) knockout studies as well as from nucleotide-based small molecule P2Y(1) antagonists has suggested that the antagonism of this receptor may offer a novel and effective method for the treatment of thrombotic disorders. Herein, we report the identification and optimization of a series of non-nucleotide P2Y(1) antagonists that are potent and orally bioavailable. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.04.028
点击查看最新优质反应信息